Cost-effectiveness analysis of current treatment of individuals with acute exacerbation of schizophrenia in Bulgaria

Biotechnology and Biotechnological Equipment

Volumn 33, Issue 1, 2019, Pages 204-213

  Ignatova, Desislava ^a   Kamusheva, Maria ^a   Petrova, Guenka ^a   Onchev, Georgi ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

cost effectiveness; costs; hospital treatment; Schizophrenia

Indexed keywords

COST EFFECTIVENESS; COSTS; DISEASES; ECONOMIC ANALYSIS; HOSPITALS; PATIENT TREATMENT; SENSITIVITY ANALYSIS;

ACUTE EXACERBATIONS; CLINICAL PRACTICES; COST EFFECTIVENESS ANALYSIS; CURRENT TREATMENTS; HEALTH CARE COSTS; LOW AND MIDDLE INCOME COUNTRIES; SCHIZOPHRENIA; WILLINGNESS TO PAY;

COST BENEFIT ANALYSIS;

EID: 85060344967     PISSN: 13102818     EISSN: None     Source Type: Journal    
DOI: 10.1080/13102818.2018.1561209     Document Type: Article

References (46)

1. Levin C, Chisholm D. Cost-effectiveness and affordability of interventions, policies, and platforms for the prevention and treatment of mental, neurological, and substance use disorders [Internet]. Mental, Neurological, and Substance Use Disorders: Disease Control Priorities, Third Edition (Volume 4). The International Bank for Reconstruction and Development/The World Bank; 2016 [cited 2017 Oct 24]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27227237
2. Emsley R, Chiliza B, Asmal L, et al. The nature of relapse in schizophrenia. BMC Psychiatr. 2013;13(1):50.
3. Lader M. What is relapse in schizophrenia? Int Clin Psychopharmacol. 1995;9(Suppl 5):5–9.
4. McGrath J, Saha S, Chant D, et al. Schizophrenia: A concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30(1):67–76.
5. Jablensky A. Worldwide burden of schizophrenia. In: Sadock BJ, Sadock VA, Ruiz P, editors. Kaplan and Sadock’s Comprehensive textbook of psychiatry. 9th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2009. p. 1451–1462.
6. Gustavsson A, Svensson M, Jacobi F, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(10):718–779.
7. Pennington M, McCrone P. The cost of relapse in schizophrenia. Pharmacoeconomics. 2017;35(9):921–936.
8. Trautmann S, Rehm J, Wittchen H-U. The economic costs of mental disorders: Do our societies react appropriately to the burden of mental disorders? EMBO Rep. 2016;17(9):1245–1249.
9. Andrews G, Sanderson K, Corry J, et al. Cost-effectiveness of current and optimal treatment for schizophrenia. Br J Psychiatry. 2003;183:427–435.
10. Knapp M, Beecham J, Koutsogeorgopoulou V, et al. Service use and costs of home-based versus hospital-based care for people with serious mental illness. Br J Psychiatry. 1994;165(2):195–203.
11. Weisbrod BA, Test MA, Stein LI. Alternative to mental hospital treatment. II. Economic benefit-cost analysis. Arch Gen Psychiatry. 1980;37(4)::400–405.
12. Stant AD, Buskens E, Jenner JA, et al. Cost-effectiveness analysis in severe mental illness: outcome measures selection. J Ment Health Policy Econ. 2007;10(2):101–108.
13. Lehman AF, Dixon L, Hoch JS, et al. Cost-effectiveness of assertive community treatment for homeless persons with severe mental illness. Br J Psychiatry. 1999;174:346–352.
14. McCrone P, Craig TKJ, Power P, et al. Cost-effectiveness of an early intervention service for people with psychosis. Br J Psychiatry. 2010;196(5):377–382.
15. Patel A, Mccrone P, Leese M, et al. Cost-effectiveness of adherence therapy versus health education for people with schizophrenia: Randomised controlled trial in four European countries. [cited 2017 Sep 15]; Available from: https://resource-allocation.biomedcentral.com/track/pdf/10.1186/1478-7547-11-12?site=resource-allocation.biomedcentral.com
16. Slade EP, Gottlieb JD, Lu W, et al. Cost-effectiveness of a ptsd intervention tailored for individuals with severe mental illness. Psychiatr Serv. 2017;68:1225–1231.
17. Lazar SG. The cost-effectiveness of psychotherapy for the major psychiatric diagnoses. Psychodyn Psychiatr. 2014;42(3):423–457.
18. Kleinman A, Estrin GL, Usmani S, et al. Time for mental health to come out of the shadows. Lancet. 2016;387(10035):2274–2275.
19. Bedrozova A, Gerdjikov I. [Economical aspects of the inpatient psychiatric help in the Republic of Bulgaria.]. Retseptor Bulg Psikhiatr Zhurnal. 2005;2(1):9–21. (in Bulgarian)
20. Knapp M, Patel A, Curran C, et al. Supported employment: cost-effectiveness across six European sites. World Psychiatry. 2013;12(1):60–68.
21. Alonso J, Petukhova M, Vilagut G, et al. Days out of role due to common physical and mental conditions: results from the WHO World Mental Health surveys. Mol Psychiatry. 2011;16(12):1234–1246.
22. Natsov I. (2012) [Clinical, Epidemiological, Psychometric and Economic Research of Patients with Multiple Somatoform Syndrome in General Medical Practice. [dissertation]. Varna, Bulgaria: Medical University of Varna (in Bulgarian).
23. Dlouhy M. Mental health policy in Eastern Europe: a comparative analysis of seven mental health systems. BMC Health Serv Res. 2014;14:42.
24. Raboch J, Kališová L, Nawka A, et al. Use of coercive measures during involuntary hospitalization: findings from ten european countries. Psychiatr Serv. 2010;61(10):1012–1017.
25. Ganev K, Onchev G, Ivanov P, A 16-year follow-up study of schizophrenia and related disorders in Sofia, Bulgaria. Acta Psychiatr Scand. 1998;98(3):200–207.
26. Sartorius N. Stigma and mental health. Lancet (London, England). 2007;370(9590):810.
27. World Health Organization (WHO). The ICD-10 classification of mental and behavioural disorders: Clinical descriptions and diagnostic guidelines. Geneva: World Health Organization; 1992. Available from: http://www.who.int/classifications/icd/en/bluebook.pdf.
28. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):26261–26276.
29. Morosini PL, Magliano L, Brambilla L, et al. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000;101(4):323–329.
30. Priebe S, Huxley P, Knight S, et al. Application and results of the Manchester short assessment of quality of life (Mansa). Int J Soc Psychiatry. 1999;45(1):7–12.
31. Reinhard SC, Gubman GD, Horwitz AV, et al. Burden assessment scale for families of the seriously mentally ill. Eval Program Plann. 1994;17(3):261–269.
32. Chisholm D, Knapp MRJ, Knudsen HC, et al. Client socio-demographic and Service Receipt Inventory–European version : development of an instrument for international research. Br J Psychiatry. 2000;177(39):s39–s33.
33. National Health Insurance Fund. National Framework for accepting volumes and prices of medical aid for 2015. http://dv.parliament.bg/DVWeb/showMaterialDV.jsp;jsessionid=30845D08DF149A4C7AF78325A5ECD7F8?idMat=91297.
34. National Center of Public Health and Analyses (NCPHA). Bulletin “Economic analysis of the activities of the medical institutions for hospital care in the public health system in the Republic of Bulgaria for the period 2010–2016”. National Center of Public.
35. National Center of Public Health and Analyses (NCPHA). Bulletin “Economic analysis of wards in multi-profile hospitals for active treatment for the period 2005-2016. National Center of Public Health and Analyses (NCPHA). 2017; http://ncphp.government.bg.
36. Ministry of Health, Bulgaria. Methodology for financing of medical establishments in 2016. Ministry of Health, Bulgaria. https://www.mh.government.bg/media/filer_public/2016/04/01/metodika_2016.pdf.
37. National Council on Prices and Reimburcement of Medical Products. Positive Drug List. Bulgaria. 2017. http://portal.ncpr.bg/registers/pages/register/list-medicament.xhtml.
38. Ministry Council, Bulgaria. Standards for financing of activities delegated by the state. 2016. http://www.minfin.bg/upload/17188/RMS+276.pdf.
39. European Central Bank, Eurosystem. Change from 11 April 2017 to 12 April 2018. https://www.ecb.europa.eu/stats/policy_and_exchange_rates/euro_reference_exchange_rates/html/eurofxref-graph-bgn.en.html.
40. Eurostat: http://appsso.eurostat.ec.europa.eu/nui/submitViewTableAction.do..
41. Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement. 2013 [cited 2017 Oct 24]; Available from: https://www.ispor.org/TaskForces/documents/CHEERS-Statement.pdf
42. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ. 2004;13(5):437–452.
43. Ganev K, Onchev G, Ivanov P. RAPyD: Sofia, Bulgaria. In: Hopper K, Harrison G, Janca A, et al., editors. Recovery from schizophrenia: An international perspective. Oxford: Oxford University Press; 2007. p. 227–239.
44. Zentner N, Baumgartner I, Becker T, et al. Course of health care costs before and after psychiatric inpatient treatment: patient-reported vs. administrative records. Int J Health Policy Manag. 2015;4(3):153–160.
45. Tan-Torres Edejer T, Baltussen R, et al., editors. WHO guide to cost-effectiveness analysis [Internet]. Geneva: WHO; 2003. Available from: http://www.who.int/choice/publications/p_2003_generalised_cea.pdf
46. Ferrari AJ, Saha S, McGrath JJ, et al. Health states for schizophrenia and bipolar disorder within the Global Burden of Disease 2010 Study. Popul Health Metr. 2012;10(1):16.